foxo4-dri senolytic or senomorphic Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment FOXO4-DRI: Human Trial Status, Cancer

The peptide effects depend on consistent use over time rather than any single dose

The elimination strategy targeting senescent cells thus represents a promising area of research in the context of various pathologies, including cancer, cardiovascular, and neurodegenerative diseases, by targeting the very biological foundation of aging

10.4103/jpn.JPN_130_19 [DOI] [PMC free article] [PubMed] [Google Scholar] Bao Z

Mass10.65 mg Result DateJuly 2, 2026 Date AddedJuly 4, 2026 View full report HPLC-UV verified per lot ~4 days to your door COA bundled with shipment Lot samples retained 5 years Overview BPC-157 (Body Protection Compound 157) is a stable 15-residue partial sequence derived from a protein found in human gastric juice